Economic evaluations of novel antipsychotic medications: a literature review (Q35068139)

6 August 2017

1 reference

title

Economic evaluations of novel antipsychotic medications: a literature review (English)

1 reference

6 August 2017

Teresa J Hudson

1 reference

6 August 2017

Greer Sullivan

1 reference

6 August 2017

Weiwei Feng

1 reference

6 August 2017

Richard R Owen

1 reference

6 August 2017

Carol R Thrush

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

published in

Schizophrenia Research

1 reference

6 August 2017

1 reference

6 August 2017

issue

2-3

1 reference

6 August 2017

page(s)

199-218

1 reference

Cost Analysis of the Treatment of Schizophrenia in the UK

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Cost Analysis of the Treatment of Schizophrenia in the UK

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Quality of life and new antipsychotics in schizophrenia. Are patients better off?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Economic and Health State Utility Determinations for Schizophrenic Patients Treated With Risperidone or Haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Risperidone versus haloperidol: II. Cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Risperidone. A pharmacoeconomic review of its use in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Impact of newer antipsychotics on outcomes in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Translating Research Into Practice: The Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Medication noncompliance and substance abuse among patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Treatment costs and patient outcomes with use of risperidone in a public mental health setting

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Datapoints: psychiatric care expenditures and length of stay: trends in industrialized countries

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Effectiveness research and implications for study design: sample size and statistical power

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Variations in the treatment culture of nursing homes and responses to regulations to reduce drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

Impact of risperidone on the use of mental health care resources

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900228-1

7 January 2021

10.1016/S0920-9964(02)00228-1

Identifiers

DOI

1 reference

6 August 2017

1 reference